Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04622085
Other study ID # RDCT-AHSK
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 6, 2021
Est. completion date May 9, 2023

Study information

Verified date October 2023
Source SciVision Biotech Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the safety and effectiveness for the correction of aging mid-face of treatment group compared with the active control group.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 9, 2023
Est. primary completion date November 4, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: 1. Age 30 to 60 years of male or female 2. MidFace Volume Deficit Scale (MFVDS) of midface graded 2 to 5 by evaluator. Exclusion Criteria: 1. Injection site with infection or other skin diseases present which may affect the evaluation 2. With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at midface 3. With permanent implants or planning to receive permanent implants during the study period at the injection sites 4. Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 6 months 5. With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period 6. With Major surgery 3 months before the start of the trial 7. With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period 8. With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.) 9. With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis movement medications 10. With epilepsy or porphyria 11. With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency 12. With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period 13. With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study 14. Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change 15. Pregnant, planning pregnancy or in breastfeeding females 16. Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ANIMERS Chiara LA
20mg/SciVision Biotech Inc.
JUVÉDERM VOLUMA®
20mg/Allergan, Inc.

Locations

Country Name City State
Taiwan Shin Kong Wu Ho-Su Memorial Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
SciVision Biotech Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate of a = 1 Grade improvement on the assessment of MidFace Volume Deficit Scale (MFVDS) The response rate is = 1 Grade improvement on the assessment of MidFace Volume Deficit Scale (MFVDS) as assessed by the evaluator at 6 months.
Evaluators assess the midface volume deficit scale (MFVDS) on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'.
6 months post-injection
Secondary Face fullness value evaluated by the digital image scoring system after injection and post 1, 3, 6, 12, 18, 24 months. The digital image scoring system analyzes the volume change (ml). A higher score means more volume increased in the midface. Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary MFVDS value evaluated by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. Evaluators assess the midface volume deficit scale on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'. Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary A Response rate of MFVDS value evaluated by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. The response rate is = 1 Grade improvement on the assessment of the MidFace Volume Deficit Scale (MFVDS) as assessed by the evaluator after injection and 1, 3, 6, 12, 18, 24 months.
Evaluators assess the midface volume deficit scale (MFVDS) on site with 5 graded scale, 0 to 5 was represented 'Fullness' to 'Severe concavity'.
Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary GAIS evaluated photographically by blinded-evaluator after injection and 1, 3, 6, 12, 18, 24 months. Evaluators and subjects assess the improvement of correction with 5 graded scale,1 to 5 was represented 'exceptional improvement' to 'worsened'. Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary VAS pain evaluated immediately and 15, 30, 45 and 60 minutes after injection The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'. Immediate,15, 30, 45 and 60 minutes post-injection
Secondary Adverse events reported during the study period The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary Serious adverse events reported during the study period The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. Immediate, 1, 3, 6, 12, 18 and 24 months post-injection
Secondary Device failure reported before injection The safety assessment was based on reports of adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded during each follow up and at any time the patient reported an event to the investigator during the study period. Before injection
See also
  Status Clinical Trial Phase
Completed NCT06355817 - Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration N/A
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04692896 - Effect of Different Concentrations of Lidocaine in Relieving Pain in Wide Awake Hand Surgery Using Tumescence Phase 1
Recruiting NCT06088875 - Nebulization Versus Spray-as-You-Go Airway Topical Anesthesia Using Dexmedetomidine and Lidocaine Mixture During Awake Flexible Fiberoptic Intubation in Temporomandibular Ankylosis N/A
Recruiting NCT04169854 - Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain Phase 3
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05089526 - Opioid-free Anesthesia in Laparoscopic Cholecystectomies N/A
Recruiting NCT03871478 - Comparing the Efficacy of Local Anesthetics in Mohs Surgery N/A
Recruiting NCT03666299 - Lidocaine Infusion for Postthoracotomy Pain Syndrome N/A
Recruiting NCT03673163 - Lidocaine Infusion for Pain After Herniotomy N/A
Recruiting NCT05158348 - A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine Phase 3
Completed NCT06135688 - Effects of Lidocaine Bolus and Infusion on Bispectral Index Values and Spectrum During Anesthesia Maintenance
Completed NCT04008433 - Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated With Medium-/Long-chain Triglycerides N/A
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT05717361 - Opioid Sparing Anesthesia in Cervical Spine Surgery N/A
Withdrawn NCT04359017 - Systemic Absorption of Lidocaine After Hematoma Block Phase 4
Recruiting NCT04144933 - Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery Phase 3
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Completed NCT05484687 - Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors N/A